Braf and erbB2 mutations correlate with smoking status in lung cancer patients

Sasaki,Hidefumi; Shitara,Masayuki; Yokota,Keisuke; Okuda,Katsuhiro; Hikosaka,Yu; Moriyama,Satoru; Yano,Motoki; Fujii,Yoshitaka

doi:10.3892/etm.2012.500

Braf and erbB2 mutations correlate with smoking status in lung cancer patients

Authors:
- Hidefumi Sasaki
- Masayuki Shitara
- Keisuke Yokota
- Katsuhiro Okuda
- Yu Hikosaka
- Satoru Moriyama
- Motoki Yano
- Yoshitaka Fujii
View Affiliations

Affiliations: Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya 467-8601, Japan
Published online on: March 1, 2012 https://doi.org/10.3892/etm.2012.500
Pages: 771-775

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The erbB pathway involves a family of tyrosine kinases and contributes to resistance or sensitivity to chemotherapy in many tumor types. Somatic mutations of the epidermal growth factor receptor (EGFR) gene at the kinase domain have been found in lung cancer patients. These mutations are correlated with clinical response to targeted molecular therapy. Although Caucasian lung cancer patients have been shown to harbor Braf and erbB2 mutations, only a few reports exist concerning Braf and erbB2 mutations in Japanese lung cancer patients. We investigated the Braf and erbB2 mutation status in non-small cell lung cancer (NSCLC) patients by reverse transcription-polymerase chain reaction (RT-PCR) and direct sequencing. The study included 305 surgically removed lung cancer samples from the Nagoya City University Hospital, which were EGFR and Kras wild-type centric. Six Braf mutations were found in the adenocarcinoma cases. Among the adenocarcinoma cases, Braf mutations were more frequently noted in heavy smokers (Brinkman index >400, p=0.0476). We also detected five erbB2 mutations all in the non-smokers. All of these mutations existed exclusively. The erbB2 gene mutations were predominantly found in non-smokers with adenocarcinomas. However, the completely exclusive mutation status could help us design individually tailored targeted molecular therapy for lung cancer.

View Figures

View References

1.	Yarden Y and Sliwkowski MX: Untangling the ErbB signaling network. Nat Rev Mol Cell Biol. 2:127–137. 2001. View Article : Google Scholar : PubMed/NCBI
2.	Rowinsky EK: The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med. 55:433–457. 2004. View Article : Google Scholar
3.	Wieduwilt MJ and Moasser MM: The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell Mol Life Sci. 65:1566–1584. 2008. View Article : Google Scholar : PubMed/NCBI
4.	Laurent-Puig P, Lievre A and Blons H: Mutations and response to epidermal growth factor receptor inhibitors. Clin Cancer Res. 15:1133–1139. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Peyssonnaux C and Eychene A: The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 93:53–62. 2001. View Article : Google Scholar : PubMed/NCBI
6.	Davies H, Bignell GR, Cox C, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
7.	Brose MS, Voipe P, Feldman M, et al: BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62:6997–7000. 2002.PubMed/NCBI
8.	Naoki K, Chen T-H, Richards WG, Sugarbaker DJ and Meyerson M: Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62:7001–7003. 2002.PubMed/NCBI
9.	Hoque MO, Brait M, Rosenbaum E, et al: Genetic and epigenetic analysis of erbB signaling pathway genes in lung cancer. J Thorac Oncol. 5:1887–1893. 2010. View Article : Google Scholar : PubMed/NCBI
10.	Paik PK, Arcila ME, Fara M, et al: Clinical characteristics of patients with lung adenocarcinomas harboring Braf mutations. J Clin Oncol. 29:2046–2051. 2011. View Article : Google Scholar : PubMed/NCBI
11.	Lee YS, Kim MJ, Jin G, et al: Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol. 5:1734–1740. 2010. View Article : Google Scholar : PubMed/NCBI
12.	Paez JG, Janne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 304:1497–1500. 2004. View Article : Google Scholar : PubMed/NCBI
13.	Sasaki H, Shimizu S, Endo K, et al: EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 118:180–184. 2006. View Article : Google Scholar : PubMed/NCBI
14.	Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Eng J Med. 350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
15.	Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from ‘never smokers’ and are associated with sensitivity of tumors to gefitinib and elrotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
16.	Sasaki H, Endo H, Konishi A, et al: EGFR mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler. Clin Cancer Res. 11:2924–2929. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Mok TS, Wu Y-L, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New Eng J Med. 361:947–957. 2009. View Article : Google Scholar : PubMed/NCBI
18.	Mitsudomi T, Morita S, Yatabe Y, et al: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer habouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomized phase 3 trial. Lancet Oncol. 11:121–128. 2010. View Article : Google Scholar
19.	Maemondo M, Inoue A, Kobayashi K, et al: Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. New Eng J Med. 362:2380–2388. 2010. View Article : Google Scholar : PubMed/NCBI
20.	Stephens P, Hunter C, Bignell G, et al: Intragenic erbB2 kinase mutations in tumors. Nature. 431:525–526. 2004. View Article : Google Scholar : PubMed/NCBI
21.	Shigematsu H, Takahashi T, Nomura M, et al: Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res. 65:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
22.	Tomizawa K, Suda K, Onozato R, et al: Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. 74:139–144. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Sasaki H, Kawano O, Endo K, et al: Uncommon V599E Braf mutations in Japanese patients with lung cancer. J Surg Res. 133:203–206. 2006. View Article : Google Scholar : PubMed/NCBI
24.	Sasaki H, Hikosaka Y, Kawano O, Moriyama S, Yano M and Fujii Y: Evaluation of Kras mutation and copy number gain in non-small cell lung cancer. J Thorac Oncol. 6:15–20. 2011. View Article : Google Scholar : PubMed/NCBI
25.	Ikenoue T, Hikiba Y, Kanai F, et al: Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res. 63:8132–8137. 2003.PubMed/NCBI
26.	Ji H, Wang Z, Perera SA, et al: Mutations in Braf and Kras converse on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. Cancer Res. 67:4933–4939. 2007. View Article : Google Scholar : PubMed/NCBI
27.	Welbrock C and Huristone A: BRAF as therapeutic target in melanoma. Biochem Pharmacol. 80:561–567. 2010. View Article : Google Scholar : PubMed/NCBI
28.	Solit DR, Garraway LA, Pratilas CA, et al: BRAF mutation predicts sensitivity to MEK inhibition. Nature. 439:358–362. 2006. View Article : Google Scholar : PubMed/NCBI
29.	Flaherty KT, Puzanov I, Kim KB, et al: Inhibition of mutated activated Braf in metastatic melanoma. N Eng J Med. 363:809–819. 2010. View Article : Google Scholar : PubMed/NCBI
30.	Minami Y, Shimamura T, Shah K, et al: The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. Oncogene. 26:5023–5027. 2007. View Article : Google Scholar : PubMed/NCBI
31.	Greulich H, Chen TH, Feng W, et al: Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2:e2132005. View Article : Google Scholar : PubMed/NCBI
32.	Sasaki H, Endo K, Takada M, et al: EGFR exon20 insertion mutation in Japanese lung cancer. Lung Cancer. 58:324–328. 2007. View Article : Google Scholar : PubMed/NCBI